{"id":13686,"date":"2024-12-05T19:01:28","date_gmt":"2024-12-05T17:01:28","guid":{"rendered":"https:\/\/maat.swebwp.oci.eu\/?p=13686"},"modified":"2024-12-05T19:02:04","modified_gmt":"2024-12-05T17:02:04","slug":"5-decembre-2024-maat-pharma-annonce-le-traitement-du-premier-patient-aux-etats-unis-avec-maat013-a-lhopital-city-of-hope-pour-la-maladie-aigue-du-greffon-contre-lhote-dans-le-programme-d","status":"publish","type":"post","link":"https:\/\/maat.swebwp.oci.eu\/fr\/5-decembre-2024-maat-pharma-annonce-le-traitement-du-premier-patient-aux-etats-unis-avec-maat013-a-lhopital-city-of-hope-pour-la-maladie-aigue-du-greffon-contre-lhote-dans-le-programme-d\/","title":{"rendered":"5 d\u00e9cembre 2024 : MaaT Pharma annonce le traitement du premier patient aux Etats-Unis avec MaaT013 \u00e0 l\u2019h\u00f4pital City of Hope pour la maladie aigu\u00eb du greffon contre l’h\u00f4te dans le programme d\u2019acc\u00e8s \u00e9largi \u00e0 usage compassionnel"},"content":{"rendered":"[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1″ background_hover_color_opacity=\u00a0\u00bb1″ column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ width=\u00a0\u00bb1\/6″ tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1″ background_hover_color_opacity=\u00a0\u00bb1″ column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ width=\u00a0\u00bb2\/3″ tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_column_text]\n

MaaT Pharma annonce le traitement du premier patient aux Etats-Unis avec MaaT013 \u00e0 l\u2019h\u00f4pital City of Hope pour la maladie aigu\u00eb du greffon contre l’h\u00f4te dans le programme d\u2019acc\u00e8s \u00e9largi \u00e0 usage compassionnel<\/span><\/h3>\n[\/vc_column_text][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1″ background_hover_color_opacity=\u00a0\u00bb1″ column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ width=\u00a0\u00bb1\/6″ tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1″ background_hover_color_opacity=\u00a0\u00bb1″ column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ width=\u00a0\u00bb1\/6″ tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1″ background_hover_color_opacity=\u00a0\u00bb1″ column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ width=\u00a0\u00bb2\/3″ tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_column_text]Lyon, France, 5 d\u00e9cembre 2024 \u2013 18h00 CET \u2013 MaaT Pharma<\/a> (EURONEXT\u00a0: MAAT – la \u00ab\u00a0Soci\u00e9t\u00e9\u00a0\u00bb), soci\u00e9t\u00e9 de biotechnologies en stade clinique avanc\u00e9, leader dans le d\u00e9veloppement de Microbiome Ecosystem TherapiesTM<\/sup> (MET)[1]<\/sup><\/a> visant \u00e0 am\u00e9liorer la survie des patients atteints de cancers gr\u00e2ce \u00e0 la modulation du syst\u00e8me immunitaire, <\/span><\/strong>annonce le premier traitement aux \u00c9tats-Unis d’un patient atteint de la maladie aigu\u00eb du greffon contre l’h\u00f4te (aGvH). Ce traitement a \u00e9t\u00e9 r\u00e9alis\u00e9 dans le cadre du programme d\u2019acc\u00e8s \u00e9largi portant sur un seul patient (Single Patient Expanded Access<\/em>) approuv\u00e9 par la Food and Drug Administration<\/em> (FDA). L’acc\u00e8s \u00e9largi, parfois appel\u00e9 \u00ab usage compassionnel \u00bb, permet \u00e0 des patients atteints de maladies graves ou mettant imm\u00e9diatement leur vie en danger<\/a> d\u2019avoir acc\u00e8s \u00e0 des m\u00e9dicaments exp\u00e9rimentaux<\/a> en dehors des essais cliniques, lorsque les options th\u00e9rapeutiques disponibles sont limit\u00e9es ou inexistantes. Aux \u00c9tats-Unis, ce programme peut \u00eatre initi\u00e9 par un m\u00e9decin traitant via une demande d\u2019autorisation pour un m\u00e9dicament exp\u00e9rimental (IND) destin\u00e9 \u00e0 un seul patient.<\/p>\n

Le patient, ayant d\u00e9j\u00e0 re\u00e7u plusieurs lignes de traitement, notamment des st\u00e9ro\u00efdes et du ruxolitinib, a \u00e9t\u00e9 trait\u00e9 avec MaaT013 \u00e0 l\u2019h\u00f4pital City of Hope par le Dr Monzr M. Al Malki, directeur du programme de greffe de cellules h\u00e9matopo\u00ef\u00e9tiques par donneur non apparent\u00e9, et le Dr Ryotaro Nakamura, professeur et directeur du Centre de greffe de cellules h\u00e9matopo\u00ef\u00e9tiques de City of Hope. City of Hope est l\u2019une des institutions les plus prestigieuses et les plus avanc\u00e9es en mati\u00e8re de canc\u00e9rologie aux \u00c9tats-Unis, son centre de r\u00e9f\u00e9rence en canc\u00e9rologie \u00e0 Los Angeles \u00e9tant class\u00e9 parmi les cinq meilleurs centres de lutte contre le cancer par le U.S. News & World Report<\/em>. Les docteurs Al Malki et Nakamura sont r\u00e9put\u00e9s pour leur expertise dans les domaines de la transplantation de cellules h\u00e9matopo\u00ef\u00e9tiques et de la GvH.<\/p>\n

\u00ab Nous sommes ravis d’avoir acc\u00e8s \u00e0 MaaT013 pour traiter ce patient atteint de GvH r\u00e9fractaire \u00bb, <\/em>a d\u00e9clar\u00e9 Dr Nakamura<\/strong>[1]<\/sup><\/a>. Dr Al Malki ajoute<\/strong> \u00ab Nous sommes convaincus que la modulation immunitaire \u00e0 travers le microbiote intestinal repr<\/em>\u00e9<\/em>sente une piste prometteuse pour le traitement de la GvH et nous sommes impatients d’explorer le potentiel de MaaT013 pour traiter la GvH et am\u00e9liorer la survie des patients. \u00bb<\/em><\/p>\n

\u00ab La mise \u00e0 disposition de MaaT013 dans le cadre d’un acc\u00e8s compassionnel aux \u00c9tats-Unis met en \u00e9vidence le besoin urgent au niveau mondial de d\u00e9velopper des th\u00e9rapies innovantes dans le traitement de l’aGvH r\u00e9fractaire \u00bb,<\/em> souligne Herv\u00e9 Affagard, directeur g\u00e9n\u00e9ral et cofondateur de MaaT Pharma.<\/strong> \u00ab Cela refl\u00e8te \u00e9galement la reconnaissance internationale croissante de MaaT013 comme un nouvel espoir potentiel pour les patients confront<\/em>\u00e9<\/em>s <\/em>\u00e0<\/em> cette maladie mortelle. \u00bb<\/em><\/p>\n

Comme communiqu\u00e9 pr\u00e9c\u00e9demment, MaaT Pharma poursuit actuellement un essai de Phase 3 ARES en Europe (NCT – 04769895<\/a>). Le recrutement des patients est d\u00e9sormais termin\u00e9 et les r\u00e9sultats principaux sont attendus en janvier 2025. MaaT Pharma pr\u00e9voit \u00e9galement d\u2019initier un essai clinique de Phase 3 aux Etats-Unis \u00e9valuant MaaT013 dans l’aGvH avec atteinte gastro-intestinale chez des sujets r\u00e9fractaires ou intol\u00e9rants au ruxolitinib. Dans ce contexte, des lots cliniques de MaaT013 ont \u00e9t\u00e9 produits, et sont \u00e9galement disponibles pour une utilisation dans le programme d\u2019acc\u00e8s \u00e9largi, sous la supervision de la FDA. Enfin, des donn\u00e9es compl\u00e9mentaires d’efficacit\u00e9, de s\u00e9curit\u00e9 et de suivi \u00e0 long terme issues du programme d’acc\u00e8s compassionnel en Europe seront pr\u00e9sent\u00e9es lors du congr\u00e8s annuel de l’American<\/em> Society of Hematology<\/em>, qui se tiendra du 7 au 10 d\u00e9cembre 2024, \u00e0 San Diego, en Californie, aux \u00c9tats-Unis.<\/p>\n

[1]<\/sup><\/a> Dr Nakamura a \u00e9t\u00e9 r\u00e9mun\u00e9r\u00e9 par MaaT Pharma pour avoir si\u00e9g\u00e9 au sein d’un advisory board<\/em>.[\/vc_column_text][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1″ background_hover_color_opacity=\u00a0\u00bb1″ column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ width=\u00a0\u00bb1\/6″ tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1″ background_hover_color_opacity=\u00a0\u00bb1″ column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ width=\u00a0\u00bb1\/6″ tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1″ background_hover_color_opacity=\u00a0\u00bb1″ column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ width=\u00a0\u00bb2\/3″ tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_column_text]A propos de MaaT Pharma<\/strong><\/span><\/p>\n

MaaT Pharma est une soci\u00e9t\u00e9 de biotechnologie en phase clinique avanc\u00e9e, leader dans le d\u00e9veloppement de m\u00e9dicaments issus du microbiote intestinal d\u00e9di\u00e9s \u00e0 moduler le syst\u00e8me immunitaire des patients atteints de cancer et \u00e0 am\u00e9liorer leur survie. Soutenue par une \u00e9quipe experte qui s’engage \u00e0 faire la diff\u00e9rence pour les patients du monde entier, la Soci\u00e9t\u00e9 a \u00e9t\u00e9 fond\u00e9e en 2014 et est bas\u00e9e \u00e0 Lyon en France.<\/p>\n

Pionni\u00e8re dans son domaine, MaaT Pharma d\u00e9veloppe le premier candidat-m\u00e9dicament immunomodulateur bas\u00e9 sur le microbiote intestinal en oncologie, actuellement en phase 3 d\u2019\u00e9valuation clinique. Gr\u00e2ce \u00e0 ses technologies propri\u00e9taires de \u00ab pooling \u00bb (combinaison de dons de microbiotes sains) et de co-culture microbienne, MaaT Pharma d\u00e9veloppe des m\u00e9dicaments standardis\u00e9s \u00e0 haute diversit\u00e9 bact\u00e9rienne, visant \u00e0 am\u00e9liorer la survie des patients atteints de cancer. MaaT Pharma est cot\u00e9e sur Euronext Paris (MAAT) depuis 2021.[\/vc_column_text][vc_column_text]A propos de MaaT013<\/strong><\/span><\/p>\n

MaaT013 est une Microbiome Ecosystem Therapy TM<\/sup> (microbioth\u00e9rapie \u00e0 \u00e9cosyst\u00e8me complet) pr\u00eate \u00e0 l\u2019emploi, standardis\u00e9e et issue d\u2019une combinaison de microbiotes de donneurs sains (pool\u00e9e). Le produit est caract\u00e9ris\u00e9 par une diversit\u00e9 et une richesse \u00e9lev\u00e9es et standardis\u00e9es des esp\u00e8ces microbiennes qu\u2019il contient et la pr\u00e9sence de ButycoreTM <\/sup>(ensemble de bact\u00e9ries produisant des m\u00e9tabolites anti-inflammatoires). MaaT013 a pour but de restaurer la relation symbiotique entre le microbiote intestinal du patient et son syst\u00e8me immunitaire, afin de corriger la r\u00e9activit\u00e9 et restaurer la tol\u00e9rance des fonctions immunitaires et ainsi de r\u00e9duire l\u2019aGvH gastro-intestinale r\u00e9sistante aux st\u00e9ro\u00efdes. MaaT013 a re\u00e7u la d\u00e9signation de m\u00e9dicament orphelin de la Food and Drug Administration (FDA) aux \u00c9tats-Unis et de l’Agence europ\u00e9enne des m\u00e9dicaments (EMA).[\/vc_column_text][vc_column_text]Donn\u00e9es prospectives <\/strong><\/span>
\nCe communiqu\u00e9 de presse contient des d\u00e9clarations prospectives. Toutes les d\u00e9clarations autres que les \u00e9nonc\u00e9s de faits historiques inclus dans le pr\u00e9sent communiqu\u00e9 de presse au sujet d’\u00e9v\u00e9nements futurs sont sujettes \u00e0 (i) des changements sans pr\u00e9avis et (ii) des facteurs ind\u00e9pendants de la volont\u00e9 de la Soci\u00e9t\u00e9. Ces d\u00e9clarations peuvent comprendre, sans s’y limiter, tout \u00e9nonc\u00e9 pr\u00e9c\u00e9d\u00e9, suivi ou incluant des mots tels que \u00ab cibler \u00bb, \u00ab croire \u00bb, \u00ab s’attendre \u00e0 \u00bb, \u00ab viser \u00bb, \u00ab avoir l’intention de \u00bb, \u00ab pouvoir \u00bb, \u00ab pr\u00e9voir \u00bb, \u00ab estimer \u00bb, \u00ab planifier \u00bb, \u00ab projeter \u00bb, \u00ab vouloir \u00bb, \u00ab pouvoir avoir \u00bb, \u00ab susceptible de \u00bb, \u00ab probable \u00bb, \u00ab devoir \u00bb, \u00ab pr\u00e9visions \u00bb et d\u2019autres mots et termes ayant un sens similaire ou la forme n\u00e9gative qui en d\u00e9coule. Les d\u00e9clarations prospectives sont assujetties \u00e0 des risques et \u00e0 des incertitudes inh\u00e9rentes ind\u00e9pendants de la volont\u00e9 de la Soci\u00e9t\u00e9 qui pourraient conduire \u00e0 ce que les r\u00e9sultats ou les performances r\u00e9els de la Soci\u00e9t\u00e9 diff\u00e8rent consid\u00e9rablement des r\u00e9sultats ou des performances attendus exprim\u00e9s ou sous-entendus dans ces d\u00e9clarations prospectives.[\/vc_column_text][image_with_animation image_url=\u00a0\u00bb6212″ animation=\u00a0\u00bbFade In\u00a0\u00bb hover_animation=\u00a0\u00bbnone\u00a0\u00bb alignment=\u00a0\u00bbcenter\u00a0\u00bb border_radius=\u00a0\u00bbnone\u00a0\u00bb box_shadow=\u00a0\u00bbnone\u00a0\u00bb image_loading=\u00a0\u00bbdefault\u00a0\u00bb max_width=\u00a0\u00bb100%\u00a0\u00bb max_width_mobile=\u00a0\u00bbdefault\u00a0\u00bb][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1″ background_hover_color_opacity=\u00a0\u00bb1″ column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ width=\u00a0\u00bb1\/3″ tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1″ background_hover_color_opacity=\u00a0\u00bb1″ column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ width=\u00a0\u00bb1\/3″ tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][nectar_btn size=\u00a0\u00bblarge\u00a0\u00bb open_new_tab=\u00a0\u00bbtrue\u00a0\u00bb button_style=\u00a0\u00bbregular\u00a0\u00bb button_color_2=\u00a0\u00bbAccent-Color\u00a0\u00bb icon_family=\u00a0\u00bbnone\u00a0\u00bb text=\u00a0\u00bbT\u00e9l\u00e9charger le communiqu\u00e9 de presse\u00a0\u00bb url=\u00a0\u00bbhttps:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2024\/12\/241205_CP-MaaT-Pharma-SPU-Version-Finale.pdf\u00a0\u00bb][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1″ background_hover_color_opacity=\u00a0\u00bb1″ column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ width=\u00a0\u00bb1\/3″ tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1″ background_hover_color_opacity=\u00a0\u00bb1″ column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ width=\u00a0\u00bb1\/1″ tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][\/vc_row]\n","protected":false},"excerpt":{"rendered":"

[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1″ background_hover_color_opacity=\u00a0\u00bb1″ column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ width=\u00a0\u00bb1\/6″ tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb…<\/p>\n","protected":false},"author":2,"featured_media":7120,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[21],"tags":[81,117,169,90,93,118,152,136,160,153,170],"category_press":[67],"year_press":[70],"class_list":{"0":"post-13686","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-communiques-de-presse-fr","8":"tag-2024-fr","9":"tag-agvhd-fr","10":"tag-cancer-fr","11":"tag-eap-fr","12":"tag-gvh-fr","13":"tag-gvhd-fr","14":"tag-hematologie","15":"tag-microbiome-fr","16":"tag-microbiote","17":"tag-oncologie-fr","18":"tag-spu-fr","19":"category_press-clinical-fr","20":"year_press-2024-2"},"acf":[],"yoast_head":"\n5 d\u00e9cembre 2024 : MaaT Pharma annonce le traitement du premier patient aux Etats-Unis avec MaaT013 \u00e0 l\u2019h\u00f4pital City of Hope pour la maladie aigu\u00eb du greffon contre l'h\u00f4te dans le programme d\u2019acc\u00e8s \u00e9largi \u00e0 usage compassionnel - MaaT Pharma<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"5 d\u00e9cembre 2024 : MaaT Pharma annonce le traitement du premier patient aux Etats-Unis avec MaaT013 \u00e0 l\u2019h\u00f4pital City of Hope pour la maladie aigu\u00eb du greffon contre l'h\u00f4te dans le programme d\u2019acc\u00e8s \u00e9largi \u00e0 usage compassionnel - MaaT Pharma\" \/>\n<meta property=\"og:description\" content=\"[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1″ background_hover_color_opacity=\u00a0\u00bb1″ column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ width=\u00a0\u00bb1\/6″ tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/maat.swebwp.oci.eu\/fr\/5-decembre-2024-maat-pharma-annonce-le-traitement-du-premier-patient-aux-etats-unis-avec-maat013-a-lhopital-city-of-hope-pour-la-maladie-aigue-du-greffon-contre-lhote-dans-le-programme-d\/\" \/>\n<meta property=\"og:site_name\" content=\"MaaT Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-05T17:01:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-05T17:02:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"MaaT Pharma\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"MaaT Pharma\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/5-decembre-2024-maat-pharma-annonce-le-traitement-du-premier-patient-aux-etats-unis-avec-maat013-a-lhopital-city-of-hope-pour-la-maladie-aigue-du-greffon-contre-lhote-dans-le-programme-d\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/5-decembre-2024-maat-pharma-annonce-le-traitement-du-premier-patient-aux-etats-unis-avec-maat013-a-lhopital-city-of-hope-pour-la-maladie-aigue-du-greffon-contre-lhote-dans-le-programme-d\/\"},\"author\":{\"name\":\"MaaT Pharma\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34\"},\"headline\":\"5 d\u00e9cembre 2024 : MaaT Pharma annonce le traitement du premier patient aux Etats-Unis avec MaaT013 \u00e0 l\u2019h\u00f4pital City of Hope pour la maladie aigu\u00eb du greffon contre l’h\u00f4te dans le programme d\u2019acc\u00e8s \u00e9largi \u00e0 usage compassionnel\",\"datePublished\":\"2024-12-05T17:01:28+00:00\",\"dateModified\":\"2024-12-05T17:02:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/5-decembre-2024-maat-pharma-annonce-le-traitement-du-premier-patient-aux-etats-unis-avec-maat013-a-lhopital-city-of-hope-pour-la-maladie-aigue-du-greffon-contre-lhote-dans-le-programme-d\/\"},\"wordCount\":2515,\"publisher\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#organization\"},\"image\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/5-decembre-2024-maat-pharma-annonce-le-traitement-du-premier-patient-aux-etats-unis-avec-maat013-a-lhopital-city-of-hope-pour-la-maladie-aigue-du-greffon-contre-lhote-dans-le-programme-d\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png\",\"keywords\":[\"2024\",\"aGvHD\",\"Cancer\",\"EAP\",\"GvH\",\"GvHD\",\"H\u00e9matologie\",\"microbiome\",\"Microbiote\",\"Oncologie\",\"SPU\"],\"articleSection\":[\"Communiqu\u00e9s de presse\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/5-decembre-2024-maat-pharma-annonce-le-traitement-du-premier-patient-aux-etats-unis-avec-maat013-a-lhopital-city-of-hope-pour-la-maladie-aigue-du-greffon-contre-lhote-dans-le-programme-d\/\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/fr\/5-decembre-2024-maat-pharma-annonce-le-traitement-du-premier-patient-aux-etats-unis-avec-maat013-a-lhopital-city-of-hope-pour-la-maladie-aigue-du-greffon-contre-lhote-dans-le-programme-d\/\",\"name\":\"5 d\u00e9cembre 2024 : MaaT Pharma annonce le traitement du premier patient aux Etats-Unis avec MaaT013 \u00e0 l\u2019h\u00f4pital City of Hope pour la maladie aigu\u00eb du greffon contre l'h\u00f4te dans le programme d\u2019acc\u00e8s \u00e9largi \u00e0 usage compassionnel - MaaT Pharma\",\"isPartOf\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/5-decembre-2024-maat-pharma-annonce-le-traitement-du-premier-patient-aux-etats-unis-avec-maat013-a-lhopital-city-of-hope-pour-la-maladie-aigue-du-greffon-contre-lhote-dans-le-programme-d\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/5-decembre-2024-maat-pharma-annonce-le-traitement-du-premier-patient-aux-etats-unis-avec-maat013-a-lhopital-city-of-hope-pour-la-maladie-aigue-du-greffon-contre-lhote-dans-le-programme-d\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png\",\"datePublished\":\"2024-12-05T17:01:28+00:00\",\"dateModified\":\"2024-12-05T17:02:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/5-decembre-2024-maat-pharma-annonce-le-traitement-du-premier-patient-aux-etats-unis-avec-maat013-a-lhopital-city-of-hope-pour-la-maladie-aigue-du-greffon-contre-lhote-dans-le-programme-d\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/maat.swebwp.oci.eu\/fr\/5-decembre-2024-maat-pharma-annonce-le-traitement-du-premier-patient-aux-etats-unis-avec-maat013-a-lhopital-city-of-hope-pour-la-maladie-aigue-du-greffon-contre-lhote-dans-le-programme-d\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/5-decembre-2024-maat-pharma-annonce-le-traitement-du-premier-patient-aux-etats-unis-avec-maat013-a-lhopital-city-of-hope-pour-la-maladie-aigue-du-greffon-contre-lhote-dans-le-programme-d\/#primaryimage\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png\",\"contentUrl\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png\",\"width\":1080,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/5-decembre-2024-maat-pharma-annonce-le-traitement-du-premier-patient-aux-etats-unis-avec-maat013-a-lhopital-city-of-hope-pour-la-maladie-aigue-du-greffon-contre-lhote-dans-le-programme-d\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/maat.swebwp.oci.eu\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"5 d\u00e9cembre 2024 : MaaT Pharma annonce le traitement du premier patient aux Etats-Unis avec MaaT013 \u00e0 l\u2019h\u00f4pital City of Hope pour la maladie aigu\u00eb du greffon contre l’h\u00f4te dans le programme d\u2019acc\u00e8s \u00e9largi \u00e0 usage compassionnel\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#website\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/\",\"name\":\"MaaT Pharma\",\"description\":\"microbiota gut to fight cancer\",\"publisher\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/maat.swebwp.oci.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#organization\",\"name\":\"Maat Pharma\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png\",\"contentUrl\":\"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png\",\"width\":150,\"height\":171,\"caption\":\"Maat Pharma\"},\"image\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34\",\"name\":\"MaaT Pharma\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"5 d\u00e9cembre 2024 : MaaT Pharma annonce le traitement du premier patient aux Etats-Unis avec MaaT013 \u00e0 l\u2019h\u00f4pital City of Hope pour la maladie aigu\u00eb du greffon contre l'h\u00f4te dans le programme d\u2019acc\u00e8s \u00e9largi \u00e0 usage compassionnel - MaaT Pharma","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"5 d\u00e9cembre 2024 : MaaT Pharma annonce le traitement du premier patient aux Etats-Unis avec MaaT013 \u00e0 l\u2019h\u00f4pital City of Hope pour la maladie aigu\u00eb du greffon contre l'h\u00f4te dans le programme d\u2019acc\u00e8s \u00e9largi \u00e0 usage compassionnel - MaaT Pharma","og_description":"[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1″ background_hover_color_opacity=\u00a0\u00bb1″ column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ width=\u00a0\u00bb1\/6″ tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb...","og_url":"https:\/\/maat.swebwp.oci.eu\/fr\/5-decembre-2024-maat-pharma-annonce-le-traitement-du-premier-patient-aux-etats-unis-avec-maat013-a-lhopital-city-of-hope-pour-la-maladie-aigue-du-greffon-contre-lhote-dans-le-programme-d\/","og_site_name":"MaaT Pharma","article_published_time":"2024-12-05T17:01:28+00:00","article_modified_time":"2024-12-05T17:02:04+00:00","og_image":[{"width":1080,"height":1080,"url":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","type":"image\/png"}],"author":"MaaT Pharma","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"MaaT Pharma","Dur\u00e9e de lecture estim\u00e9e":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/maat.swebwp.oci.eu\/fr\/5-decembre-2024-maat-pharma-annonce-le-traitement-du-premier-patient-aux-etats-unis-avec-maat013-a-lhopital-city-of-hope-pour-la-maladie-aigue-du-greffon-contre-lhote-dans-le-programme-d\/#article","isPartOf":{"@id":"https:\/\/maat.swebwp.oci.eu\/fr\/5-decembre-2024-maat-pharma-annonce-le-traitement-du-premier-patient-aux-etats-unis-avec-maat013-a-lhopital-city-of-hope-pour-la-maladie-aigue-du-greffon-contre-lhote-dans-le-programme-d\/"},"author":{"name":"MaaT Pharma","@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34"},"headline":"5 d\u00e9cembre 2024 : MaaT Pharma annonce le traitement du premier patient aux Etats-Unis avec MaaT013 \u00e0 l\u2019h\u00f4pital City of Hope pour la maladie aigu\u00eb du greffon contre l’h\u00f4te dans le programme d\u2019acc\u00e8s \u00e9largi \u00e0 usage compassionnel","datePublished":"2024-12-05T17:01:28+00:00","dateModified":"2024-12-05T17:02:04+00:00","mainEntityOfPage":{"@id":"https:\/\/maat.swebwp.oci.eu\/fr\/5-decembre-2024-maat-pharma-annonce-le-traitement-du-premier-patient-aux-etats-unis-avec-maat013-a-lhopital-city-of-hope-pour-la-maladie-aigue-du-greffon-contre-lhote-dans-le-programme-d\/"},"wordCount":2515,"publisher":{"@id":"https:\/\/maat.swebwp.oci.eu\/#organization"},"image":{"@id":"https:\/\/maat.swebwp.oci.eu\/fr\/5-decembre-2024-maat-pharma-annonce-le-traitement-du-premier-patient-aux-etats-unis-avec-maat013-a-lhopital-city-of-hope-pour-la-maladie-aigue-du-greffon-contre-lhote-dans-le-programme-d\/#primaryimage"},"thumbnailUrl":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","keywords":["2024","aGvHD","Cancer","EAP","GvH","GvHD","H\u00e9matologie","microbiome","Microbiote","Oncologie","SPU"],"articleSection":["Communiqu\u00e9s de presse"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/maat.swebwp.oci.eu\/fr\/5-decembre-2024-maat-pharma-annonce-le-traitement-du-premier-patient-aux-etats-unis-avec-maat013-a-lhopital-city-of-hope-pour-la-maladie-aigue-du-greffon-contre-lhote-dans-le-programme-d\/","url":"https:\/\/maat.swebwp.oci.eu\/fr\/5-decembre-2024-maat-pharma-annonce-le-traitement-du-premier-patient-aux-etats-unis-avec-maat013-a-lhopital-city-of-hope-pour-la-maladie-aigue-du-greffon-contre-lhote-dans-le-programme-d\/","name":"5 d\u00e9cembre 2024 : MaaT Pharma annonce le traitement du premier patient aux Etats-Unis avec MaaT013 \u00e0 l\u2019h\u00f4pital City of Hope pour la maladie aigu\u00eb du greffon contre l'h\u00f4te dans le programme d\u2019acc\u00e8s \u00e9largi \u00e0 usage compassionnel - MaaT Pharma","isPartOf":{"@id":"https:\/\/maat.swebwp.oci.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/maat.swebwp.oci.eu\/fr\/5-decembre-2024-maat-pharma-annonce-le-traitement-du-premier-patient-aux-etats-unis-avec-maat013-a-lhopital-city-of-hope-pour-la-maladie-aigue-du-greffon-contre-lhote-dans-le-programme-d\/#primaryimage"},"image":{"@id":"https:\/\/maat.swebwp.oci.eu\/fr\/5-decembre-2024-maat-pharma-annonce-le-traitement-du-premier-patient-aux-etats-unis-avec-maat013-a-lhopital-city-of-hope-pour-la-maladie-aigue-du-greffon-contre-lhote-dans-le-programme-d\/#primaryimage"},"thumbnailUrl":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","datePublished":"2024-12-05T17:01:28+00:00","dateModified":"2024-12-05T17:02:04+00:00","breadcrumb":{"@id":"https:\/\/maat.swebwp.oci.eu\/fr\/5-decembre-2024-maat-pharma-annonce-le-traitement-du-premier-patient-aux-etats-unis-avec-maat013-a-lhopital-city-of-hope-pour-la-maladie-aigue-du-greffon-contre-lhote-dans-le-programme-d\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/maat.swebwp.oci.eu\/fr\/5-decembre-2024-maat-pharma-annonce-le-traitement-du-premier-patient-aux-etats-unis-avec-maat013-a-lhopital-city-of-hope-pour-la-maladie-aigue-du-greffon-contre-lhote-dans-le-programme-d\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/maat.swebwp.oci.eu\/fr\/5-decembre-2024-maat-pharma-annonce-le-traitement-du-premier-patient-aux-etats-unis-avec-maat013-a-lhopital-city-of-hope-pour-la-maladie-aigue-du-greffon-contre-lhote-dans-le-programme-d\/#primaryimage","url":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","contentUrl":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","width":1080,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/maat.swebwp.oci.eu\/fr\/5-decembre-2024-maat-pharma-annonce-le-traitement-du-premier-patient-aux-etats-unis-avec-maat013-a-lhopital-city-of-hope-pour-la-maladie-aigue-du-greffon-contre-lhote-dans-le-programme-d\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/maat.swebwp.oci.eu\/fr\/"},{"@type":"ListItem","position":2,"name":"5 d\u00e9cembre 2024 : MaaT Pharma annonce le traitement du premier patient aux Etats-Unis avec MaaT013 \u00e0 l\u2019h\u00f4pital City of Hope pour la maladie aigu\u00eb du greffon contre l’h\u00f4te dans le programme d\u2019acc\u00e8s \u00e9largi \u00e0 usage compassionnel"}]},{"@type":"WebSite","@id":"https:\/\/maat.swebwp.oci.eu\/#website","url":"https:\/\/maat.swebwp.oci.eu\/","name":"MaaT Pharma","description":"microbiota gut to fight cancer","publisher":{"@id":"https:\/\/maat.swebwp.oci.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/maat.swebwp.oci.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/maat.swebwp.oci.eu\/#organization","name":"Maat Pharma","url":"https:\/\/maat.swebwp.oci.eu\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/","url":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","contentUrl":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","width":150,"height":171,"caption":"Maat Pharma"},"image":{"@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34","name":"MaaT Pharma"}]}},"_links":{"self":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/posts\/13686","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/comments?post=13686"}],"version-history":[{"count":0,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/posts\/13686\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/media\/7120"}],"wp:attachment":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/media?parent=13686"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/categories?post=13686"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/tags?post=13686"},{"taxonomy":"category_press","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/category_press?post=13686"},{"taxonomy":"year_press","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/year_press?post=13686"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}